暗盘资金一眼洞悉庄家意图>> 牙科医疗板块盘初拉升，皓宸医疗（002622）封板涨停，爱迪特（301580）涨超5%，康惠制药 （603139）、悦心健康（002162）、正海生物（300653）、国瓷材料（300285）等均涨超2%。 ...

爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）董事会于近日 收到公司副总经理解万东先生提交的书面辞职报告，解万东先生因个人原因， 申请辞去公司副总经理职务，辞任后不再担任公司任何职务。解万东先生的辞 职报告自送达董事会之日起生效，其辞职不会对公司经营产生影响。 解万东先生原定任期届满日为 2027 年 4 月 8 日，截至本公告披露日，解万 东先生未直接持有公司股份，其通过持股平台同源（天津）企业管理中心（有 限合伙）间接持有公司股份 8 万股，占公司总股本的 0.105%，其配偶或其他关 联人未持有公司股份。解万东先生辞职后，其股份变动将严格遵守《深圳证券 交易所上市公司自律监管指引第 10 号——股份变动管理》《深圳证券交易所上 市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》《上市 公司董事和高级管理人员所持本公司股份及其变动管理规则（2025 年修订）》 等法律法规的要求以及在《首次公开发行股票并在创业板上市招股说明书》 《首次公开发行股票并在创业板上市之上市公告书》里所作出的承诺。 公司及董事会对解万东先生在任职期间的勤勉工作及对公司发展所作出的 贡献表示衷心感谢。 特此公 ...

证券代码： 301580 证券简称：爱迪特 公告编号： 2025-018 爱迪特（秦皇岛）科技股份有限公司 2. 自分配方案披露至实施期间公司股本总额未发生变化。 3. 本次实施的分配方案与股东会审议通过的分配方案一致，未发生调整情 形。 4. 本次实施分配方案距离股东会审议通过的时间未超过两个月。 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"） 2024 年年度权 益分派方案已获 2025 年 5 月 21 日召开的 2024 年年度股东会审议通过，现将权 益分派事宜公告如下： 一、股东会审议通过利润分配方案等情况 1. 公司于 2025 年 5 月 21 日召开的 2024 年年度股东会审议通过的 2024 年年 度利润分配方案为： 以公司现有总股本 76,117,527 股为基数，向全体股东每 10 股派发现金红利 6.5元（含税），合计派发现金股利49,476,392.55 元（含税）， 同时以资本公积金向全体股东每 10 股转增 4 股，合计转增 30,447,0 ...

Group 1: Company Advantages - Brand Strength: The company promotes its own brand overseas and establishes subsidiaries in key markets to enhance service reach [1] - R&D Capability: The company emphasizes product development, with R&D personnel accounting for 15.12% of the workforce in 2024, totaling 145 staff [1] - Product Portfolio: The company offers a diverse range of dental restoration materials, including dental crowns, implant bases, and implants, along with self-developed digital dental equipment [1] Group 2: Development Strategy - Market Insight: The company continuously analyzes market trends and customer needs to build a comprehensive product system and penetrate global markets [2] - Future Planning: The company is strategically positioning itself in implant systems, complete dentures, and 3D printing to support mid- to long-term growth [2] - Resource Integration: The company focuses on external development opportunities and aims to integrate cutting-edge technologies globally [2] Group 3: Market Drivers - Domestic Market: Digital penetration in the supply chain will standardize dental processing, driven by aging population and increased oral health awareness [2] - International Markets: Mature markets like Europe and the U.S. show steady growth with strong payment capabilities for digital products, while emerging markets present structural opportunities [2] Group 4: Material Comparison - Zirconia vs. Glass Ceramics: These materials serve different clinical needs; glass ceramics are used for aesthetic repairs, while zirconia is versatile for various restorations [2] Group 5: Overseas Sales Strategy - Subsidiary Establishment: The company has set up subsidiaries in mature markets like the U.S., Germany, South Korea, and Japan to enhance service capabilities [3] - Sales Model: A "direct sales + distribution" model is employed in the U.S. and Europe to provide comprehensive pre- and post-sales support [3] - Market Management: The company focuses on matching customer needs, strengthening brand presence, and enhancing local team capabilities to improve market share [3]

Group 1: Company Growth and Market Strategy - The company aims to enhance its industry position through technological innovation and digital transformation in the dental sector, focusing on external growth opportunities via investments and acquisitions [1] - The long-term outlook for the dental digital equipment business is positive, driven by factors such as aging population, rising economic levels, and increased awareness of oral care, indicating a broad market potential [2] Group 2: Revenue and Market Distribution - In the first half of 2024, domestic revenue accounted for 41.22%, highlighting the significant growth potential and policy support in the Chinese market, which serves as a foundation for global expansion [3] - The company has a balanced distribution of sales across over 100 countries and regions, including Europe, North America, Asia, South America, and Australia, which helps mitigate risks associated with reliance on a single market [3] Group 3: Production and Operational Preparedness - The company has established a production base in South Korea after acquiring a controlling stake in a local firm, primarily for the production of implant systems [4] - Ongoing automation upgrades in production lines are aimed at ensuring stable product supply and manageable operational costs for overseas production bases [4]

北京市中伦律师事务所 关于爱迪特（秦皇岛）科技股份有限公司 2024 年年度股东会的 法律意见书 致：爱迪特（秦皇岛）科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受爱迪特（秦皇岛）科技股 份有限公司（以下简称"公司"）的委托，指派本所律师对公司 2024 年年度股 东会（以下简称"本次股东会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）和《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等现行有效的法律、法规、规范性文件 以及《爱迪特（秦皇岛）科技股份有限公司章程》（以下简称"《公司章程》"）、 《爱迪特（秦皇岛）科技股份有限公司股东会议事规则》（以下简称"《股东会 议事规则》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件、扫描件等材料 ...

爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）2024 年年度股 东会（以下简称"股东会"）现场会议于 2025 年 5 月 21 日下午 14:30 在河北省 秦皇岛市经济技术开发区都山路 9 号公司二楼会议室召开；同时使用深圳证券 交易所交易系统网络投票于 2025 年 5 月 21 日交易时间接受网络投票，即 9:15- 9:25，9:30-11:30和13:00-15:00；使用深圳证券交易所互联网投票系统于2025年 5 月 21 日 9:15-15:00 期间接受网络投票。 股东出席的总体情况：出席本次股东会的股东及股东的委托代理人共计 74 人，代表公司有表决权的股份 26,051,118 股，占公司有表决权股份总数的 34.2249%。其中，参加现场会议的股东及股东代表 6 人，代表公司有表决权的 股份 25,894,418 股，占公司有表决权股份总数的 34.0190%；参加网络投票的股 东及股东代表 68 人，代表公司有表决权的股份 156,700 股，占公司有表决权股 份总数的 0.2059%。 证券代码： 301580 证券简称：爱迪特 公告编号： 2025-017 爱迪特（秦皇 ...

Group 1: Company Performance Outlook - The company expects its performance in 2025 to exceed that of the previous year, adjusting strategies based on market conditions [2] - In the first half of 2024, domestic revenue accounted for 41.22%, indicating significant growth potential in the Chinese market [2] - The company aims for substantial revenue growth from its acquisition of Korean Wolan in 2025, focusing on market expansion and brand building [2] Group 2: Product Pricing and Market Strategy - Product prices remain stable, with changes primarily due to sales structure and tiered pricing policies [2] - The company has a balanced distribution of sales across multiple regions, including Europe, North America, Asia, South America, and Australia, reducing reliance on any single market [2] - Most tariffs on products exported to the U.S. are borne by customers, mitigating operational risks for the company [2] Group 3: Innovations and Digital Solutions - The company is responding to the digitalization needs in orthodontics by offering comprehensive digital solutions, including 3D printing technology [4] - In 2025, the company will upgrade its milling machine series and launch a 49-minute rapid sintering furnace, alongside advancements in 3D printing products [6] - The introduction of 3D printed full dentures and precise implant solutions for edentulous patients marks a significant innovation in the company's offerings [8] Group 4: Overseas Market Development - The company emphasizes matching customer needs in overseas markets and enhancing brand presence through training and relationship building [7] - Following the acquisition of Korean Wolan, the company is exploring the feasibility of establishing production bases in Europe and Asia [10] - The company is actively investing in channel development and market penetration to seize opportunities in the growing dental implant sector [9]

中信建投证券股份有限公司 关于爱迪特（秦皇岛）科技股份有限公司 2024 年度持续督导跟踪报告 | 保荐人名称：中信建投证券股份有限公司 | 上市公司简称：爱迪特 | | --- | --- | | 保荐代表人姓名：张铁 | 联系电话：021-68801592 | | 保荐代表人姓名：周俊峰 | 联系电话：010-86451688 | 二、保荐人发现公司存在的问题及采取的措施 | 事 项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 无 | 不适用 | | 2.公司内部制度的建立和执行 | 无 | 不适用 | | 3."三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人变动 | 无 | 不适用 | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.收购、出售资产 | 无 | 不适用 | | 9.其他业务类别重要事项（包括 对外投资、风险投资、委托理财、 | 无 | 不适用 | | 财务资助、套期保值等） | | | | 10.发行人或者其聘请的中介机 ...

Core Viewpoint - The company, Aidi Te (301580.SZ), is experiencing rapid business growth in the dental restoration materials and digital dental equipment sector, leveraging digitalization to connect clinical and technical aspects of dental services, while focusing on consumer needs [1][2]. Group 1: Financial Performance - In 2024, Aidi Te achieved a revenue of 888 million yuan, a year-on-year increase of 13.81% [1]. - The net profit attributable to shareholders was 150 million yuan, up 2.40% from the previous year, while the net profit after deducting non-recurring gains and losses was 145 million yuan, reflecting a growth of 9.32% [1]. - The company plans to distribute a cash dividend of 0.49 million yuan (including tax) and a capital reserve conversion of 30.45 million shares, with a cash dividend ratio of 32.88% of the annual net profit [1]. Group 2: Research and Development - Aidi Te invested 47.36 million yuan in R&D during the reporting period, marking an 18.21% increase year-on-year [2]. - The company has developed a comprehensive product R&D system covering various aspects of the dental industry, including new dental restoration materials and digital equipment [2]. - The synergy between the digital equipment and restoration materials enhances market competitiveness and promotes digital transformation in the traditional dental industry [2]. Group 3: Market Position and Growth Outlook - Aidi Te has established a strong presence in the domestic dental medical industry, with its products distributed across major provinces and cities in China, and has also made significant inroads into international markets [2]. - The company is expected to maintain a growth trajectory due to its leading position in dental restoration materials and digital equipment, supported by robust R&D and a global sales network [2]. - In Q1 2025, Aidi Te reported a revenue of 205 million yuan, an 18.07% increase year-on-year, and a net profit of 31.27 million yuan, reflecting a substantial growth of 34.21% [3]. - The company aims to enhance its growth-oriented business and improve operational efficiency through strategic planning and market expansion in 2025 [3].